BIG
LXRX icon

Boothe Investment Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Boothe Investment Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-467,919
Closed -$2.04M – 35
2021
Q2 		$2.04M Buy
467,919
+31,980
+7% +$154K 1.07% 24
2021
Q1 		$2.56M Buy
+435,939
New +$3.02M 1.49% 24

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boothe Investment Group's LXRX Position: Q3 2021 in Review

Boothe Investment Group sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2021, closing a stake of 467,919 shares — an estimated $2.04M sold.

Boothe Investment Group first reported a position in LXRX in Q1 2021 and held it in 2 quarters. The position peaked at $2.56M in Q1 2021. 96 funds tracked by Wall St. Rank hold LXRX as of Q3 2021.

  • Boothe Investment Group reported no remaining Lexicon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Boothe Investment Group sold 467,919 Lexicon Pharmaceuticals shares in Q3 2021, an estimated $2.04M.
  • Boothe Investment Group first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Boothe Investment Group's Lexicon Pharmaceuticals position peaked at $2.56M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2021.

Based on Boothe Investment Group's 13F filing for Q3 2021, filed 6 Oct 2021.